News Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 2025-03-21			5-day change	1st Jan Change
186,700.00 ^KRW	+0.21%		+0.32%	-0.43%

Mar. 20	Celltrion Inc To Acquire 50 Billion Won Worth Of Its Own Shares	RE
Mar. 20	Celltrion, Inc. announces an Equity Buyback for 268,385 shares.	CI

Celltrion Inc To Acquire 50 Billion Won Worth Of Its Own Shares	Mar. 20	RE
Celltrion, Inc. announces an Equity Buyback for 268,385 shares.	Mar. 20	CI
Celltrion, Inc. authorizes a Buyback Plan.	Mar. 20	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on February 19, 2025.	Mar. 20	CI
Celltrion Submits Plan For Phase 3 Clinical Trials For Darzalex Biosimilar Ct-P44 To South Korean Regulator	Mar. 20	RE
Celltrion Targets KRW5 Trillion in Sales in 2025 on Expanded Biosimilar Lineup	Mar. 19	MT
Celltrion, Inc.'s Equity Buyback announced on February 19, 2025, has closed with 554,632 shares, representing 0.26% for KRW 101,798.06 million.	Mar. 18	CI
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 17	CI
Nomura Adjusts Celltrion's Price Target to KRW240,000 From KRW230,000, Keeps at Buy	Mar. 17	MT
Celltrion Launches Autoimmune Disease Treatment Biosimilar in US	Mar. 14	MT
Celltrion's Infliximab Is Now Remdantry in Canada	Mar. 11	CI
U.S. FDA approves Celltrion's OMLYCLO as the first and only biosimilar with interchangeability designation referencing XOLAIR	Mar. 10	AQ
U.S. FDA Approves Celltrion Inc's Omlyclo, Biosimilar To Xolair	Mar. 07	RE
Celltrion : Investor Presentation March & April 2025	Mar. 06	PU
Celltrion's Denosumab Biosimilars Get FDA Approval, US Launch Set for June	Mar. 04	MT
Celltrion Receives U.S. FDA Approval for STOBOCLO (denosumab-bmwo) and OSENVELT Biosimilarars Referencing PROLIA and XGEVA	Mar. 03	CI
South Korean shares fall as Nvidia-supplier SK Hynix drags	Feb. 26	RE
Celltrion Shares Jump 9% on Over 22,000% Surge in Q4 Net Attributable Income	Feb. 26	MT
South Korean Shares Dip Amid Economic Concerns, Rate Cut	Feb. 25	MT
Celltrion : FY2024, 4Q24 Earning Release Celltrion Inc.	Feb. 25	PU
Celltrion Secures European Commission Approval for Three Biosimilars	Feb. 24	MT
Celltrion Presents New LIBERTY Study Analyses on SC Infliximab at ECCO 2025	Feb. 24	MT
Celltrion's Avtozma Secures EU Approval for Autoimmune Disease Treatment	Feb. 24	MT
Celltrion Receives EC Approval for Avtozma, a Biosimilar to RoActemra	Feb. 24	AQ
Celltrion Receives EC Approval for Avtozma® (CT-P47), A Biosimilar to Roactemra® (tocilizumab)	Feb. 23	CI

4408d5bd06f1634.rpiad-sJvkbVF8q0gl9PD3wze2jsBPo4wEMp_YP79z0.4dHYQphq_ySZJajC4SUtajZDAwGiTYhetQhPuseUnQmeoPICh2TrCeBZkw

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Filters